Myotonic Dystrophy Type 1 and Resistance Exercise

Learn more about:
Related Clinical Trial
DMCRN-02-001: Assessing Pediatric Endpoints in DM1 Myotonic Dystrophy Type 1 and Resistance Exercise Phase 1/2 Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AOC 1001 Administered Intravenously to Adult Myotonic Dystrophy Type 1 (DM1) Patients Biomarker Development for Muscular Dystrophies Extracellular RNA Biomarkers of Myotonic Dystrophy Symptoms and Outcome Measures for Upper- Limb Function in Myotonic Dystrophy Type 1 Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myotonic Dystrophy Type 1 Poor Neck Proprioception May Cause Balance Deficits in Myotonic Dystrophy 1 Myotonic Dystrophy – Vascular and Cognition Effect of MYODM on Quality of Life, Fatigue and Hypersomnia in Patients With Myotonic Dystrophy Type 1 Open Label Study in Adolescents and Children With Myotonic Disorders European Home Mechanical Ventilation Registry Effects of SomatoKine (Iplex)Recombinant Human Insulin-like Growth Factor-1/Recombinant Human Insulin-like Growth Factor-binding Protein-3 (rhIGF-I/rhIGFBP-3) in Myotonic Dystrophy Type 1 (DM1) Safety and Efficacy Study of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3) In Myotonic Dystrophy Type 1 A Safety andTolerability Study of Multiple Doses of ISIS-DMPKRx in Adults With Myotonic Dystrophy Type 1 Sleep Breathing Disorders, a Main Trigger for Cardiac ARythmias in Type I Myotonic Dystrophy ? Safety, Tolerability and Pharmacokinetics of ERX-963 in Adults With Myotonic Dystrophy Type 1 Effects of a 12-week Strength Training Program in Men With Myotonic Dystrophy Type 1 Efficacy and Safety of DHEA for Myotonic Dystrophy Study of Tideglusib in Adolescent and Adult Patients With Myotonic Dystrophy Effects of a Multiple Component Training Program on Muscles in Adults With Myotonic Dystrophy Type 1 Ventilatory Response After Non Invasive Ventilation in Type 1 Myotonic Dystrophy Clinical Efficacy Trial of Mexiletine for Myotonic Dystrophy Type 1 DM-IMT – Controlled, Randomized, Three-arm Intervention Study on the Safety and Efficacy of Regular Respiratory Muscle Training in Patients With Myotonic Dystrophy Type 1 Venous Thromboembolism in DM1 Postural Spirometry Changes in Ambulatory Myotonic Dystrophy Patients Factors Associated With Hypoventilation in the Myotonic Dystrophy, Progressive Profile Over 5 Years PhenoDM1 (Myotonic Dystrophy Type 1 Natural History Study) Children’s Health Research Institute(CHRI), Stanford Lucile Packard Children Hospital (LPCH) Protocol on Myotonic Dystrophy Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1) Observational Prolonged Trial in Myotonic Dystrophy Type 1 Venous Thromboembolism in Myotonic Dystrophy Type 1 Myotonic Dystrophy Type 1 Aerobic Exercise Study Multicenter Observational Study of Myotonic Dystrophy Type 1 DM1 Heart Registry – DM1 Respiratory Registry

Brief Title

Myotonic Dystrophy Type 1 and Resistance Exercise

Official Title

Recovery After Moderate-Heavy Resistance Exercise in Myotonic Dystrophy Type 1-patients

Brief Summary

      The purpose of this study is to investigate the response after one bout of moderate-heavy
      resistance exercise in patients suffering from Myotonic Dystrophy type 1. There is still
      doubt about if these patients could benefit from resistance exercise, or if this mode of
      exercise is detrimental to their mobility and health. We aim to monitor the subjects during
      the recovery phase and investigate recovery in several ways.
    

Detailed Description

      Myotonic dystrophy type 1 (DM1) is an autosomal, dominantly inherited, muscular disease and
      the most common muscular dystrophy amongst adults. The disease is characterized by
      progressive myopathy and myotonia, first evident in the distal parts of the body: calves and
      forearms, further progressing towards proximal parts. A recent review by Voet and co-workers
      (2013) concludes that exercise is safe for DM1-patients, and based on our current knowledge,
      DM1-patients should be able to gain positive adaptations from exercise. However, the
      physiological outcomes of an exercise stimulus are not well studied in this population and
      because of alterations in important Ca2+ handling systems the recovery processes might be
      significantly different from healthy muscles.

      The aim of this study is to investigate the acute responses to moderate-heavy resistance
      exercise in DM1-patients. We aim to establish a timeline for recovery of muscle strength,
      measured as maximal voluntary contraction. In line with this, we want to investigate if any
      muscular damage has occurred with both direct and indirect measures, and possible mechanisms
      leading to muscle damage, i.e. impaired Ca2+ handling.
    


Study Type

Interventional


Primary Outcome

Change in muscle strength

Secondary Outcome

 Muscle protein synthesis rate

Condition

Myotonic Dystrophy 1

Intervention

Moderate-Heavy Resistance Exercise

Study Arms / Comparison Groups

 DM1-Ex
Description:  Moderate-heavy resistance exercise of one leg in DM1-patients

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Other

Estimated Enrollment

32

Start Date

June 14, 2021

Completion Date

March 2022

Primary Completion Date

March 2022

Eligibility Criteria

        Inclusion Criteria:

          -  Confirmed Myotonic Dystrophy type 1-diagnosis

        Exclusion Criteria:

          -  Non-ambulatory

          -  Injuries to muscle-skeletal-system that prevents resistance exercise

          -  Severe affection of the cardiovascular system

          -  Cognitive affection

          -  Lives more than one hour from test site
      

Gender

All

Ages

18 Years - 40 Years

Accepts Healthy Volunteers

Accepts Healthy Volunteers

Contacts

Truls Raastad, PhD, +47 23 26 23 28, [email protected]

Location Countries

Norway

Location Countries

Norway

Administrative Informations


NCT ID

NCT05036447

Organization ID

STYRK DM1


Responsible Party

Principal Investigator

Study Sponsor

Norwegian School of Sport Sciences

Collaborators

 Oslo University Hospital

Study Sponsor

Truls Raastad, PhD, Principal Investigator, Norwegian School of Sport Sciences


Verification Date

August 2021